A phase III randomized multicenter trial evaluating cognition in post-menopausal breast cancer patients receiving adjuvant hormonotherapy

详细信息    查看全文

• 作者：Emilie Le Rhun ; Xavier Delbeuck…
• 关键词：Cognitive disorders ; Breast cancer ; Hormonotherapy ; Aromatase inhibitors ; Tamoxifen ; Chemobrain
• 刊名：Breast Cancer Research and Treatment
• 出版年：2015
• 出版时间：August 2015
• 年：2015
• 卷：152
• 期：3
• 页码：569-580
• 全文大小：817 KB
• 参考文献：1.Early Breast Cancer Trialists-Collaborative Group (1988) Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. N Engl J Med 319:1681-692. doi:10.-056/?NEJM198812293192-01 View Article
  2.Dowsett M, Cuzick J, Howell A et al (2001) Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the “Arimidex and tamoxifen alone or in combination-(ATAC) trial. Br J Cancer 85:317-24. doi:10.-054/?bjoc.-001.-925 PubMed View Article
  3.Shughrue P, Scrimo P, Lane M et al (1997) The distribution of estrogen receptor-beta mRNA in forebrain regions of the estrogen receptor-alpha knockout mouse. Endocrinology 138:5649-652. doi:10.-210/?endo.-38.-2.-712 PubMed
  4.Roselli CE, Klosterman SA, Fasasi TA (1996) Sex differences in androgen responsiveness in the rat brain: regional differences in the induction of aromatase activity. Neuroendocrinology 64:139-45PubMed View Article
  5.Yague JG, Azcoitia I, DeFelipe J et al (2010) Aromatase expression in the normal and epileptic human hippocampus. Brain Res 1315:41-2. doi:10.-016/?j.?brainres.-009.-9.-11 PubMed View Article
  6.Klepin HD, Geiger AM, Bandos H et al (2014) Cognitive factors associated with adherence to oral antiestrogen therapy: results from the cognition in the study of tamoxifen and raloxifene (Co-STAR) study. Cancer Prev Res Phila Pa 7:161-68. doi:10.-158/-940-6207.?CAPR-13-0165 View Article
  7.Paganini-Hill A, Clark LJ (2000) Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 64:165-76PubMed View Article
  8.Schilder CM, Seynaeve C, Beex LV et al (2010) Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol Off J Am Soc Clin Oncol 28:1294-300. doi:10.-200/?JCO.-008.-1.-553 View Article
  9.Bender CM, Sereika SM, Brufsky AM et al (2007) Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause N Y N 14:995-98. doi:10.-097/?gme.-b013e318148b28b-/span> View Article
  10.Salmaso D, Longoni AM (1985) Problems in the assessment of hand preference. Cortex J Devot Study Nerv Syst Behav 21:533-49View Article
  11.Mackinnon A, Mulligan R (2005) The estimation of premorbid intelligence levels in French speakers. L’Encéphale 31:31-3PubMed View Article
  12.McNair DM, Kahn RJ (1983) Self assessment of cognitive deficits. In: Crook T, Ferris S, Bartus R (eds) Assessment in geriatric psychopharmacology. Mark Powley Associates, New Canaan, pp 137-43
  13.Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state- A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-98PubMed View Article
  14.Rey A (1964) L’Examen Clinique en Psychologie. Presses Universitaires de France, Paris
  15.Benton AL, de Hamsher KS, Varney NR, Spreen O (1983) Contributions to neuropsychological assessment: a clinical manual. Oxford University Press, New York
  16.Wechsler D (1981) WAIS-R. manual. The Psychological Corporation, New York, p 156
  17.Wechsler D (1987) Wechsler memory scale-revised. Psychological Corporation, San Antonio
  18.Reitan RM (1958) Validity of the trail making test as an indicator of organic brain damage. Percept Mot Skills 8:271-86View Article
  19.Stroop JR (1935) Studies of interference in serial verbal reaction. J Exp Psychol 18:643-62View Article
  20.Cardebat D, Doyon B, Puel M et al (1990) Formal and semantic lexical evocation in normal subjects. Performance and dynamics of production as a function of sex, age and educational level. Acta Neurol Belg 90:207-17PubMed
  21.Nelson HE (1976) A modified card sorting test sensitive to frontal lobe defects. Cortex J Devot Study Nerv Syst Behav 12:313-24View Article
  22.Aaronson NK, Ahmedzai S, Bergman B et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-76PubMed View Article
  23.Barberger-Gateau P, Dartigues JF, Letenneur L (1993) Four instrumental activities of daily living score as a predictor of one-year incident dementia. Age Ageing 22:457-63PubMed View Article
  24.Shilling V, Jenkins V, Trapala IS (2006) The (mis)classification of chemo-fog–methodological inconsistencies in the investigation of cognitive impairment after chemotherapy. Breast Cancer Res Treat 95:125-29. doi:10.-007/?s10549-005-9055-1 PubMed View Article
  25.Ganz PA, Petersen L, Castellon SA et al (2014) Cognitive function after the initiation of adjuvant endocrine therapy i
• 作者单位：Emilie Le Rhun (1) (2) (3)
  Xavier Delbeuck (4)
  Claudia Lefeuvre-Plesse (5)
  Andrew Kramar (6)
  Emilie Skrobala (7)
  Florence Pasquier (4)
  Jacques Bonneterre (8) (9)
  
  1. Neurology, Breast Cancer Unit, Oscar Lambret Center, 3 Rue Frederic Combemale, 59 020, Lille Cedex, France
  2. Neurooncology, University Hospital, Lille, France
  3. Inserm U1192, Villeneuve d’Ascq, France
  4. Inserm U1171 and Memory Center, University Hospital and University of Lille, Lille, France
  5. Breast Unit, Department of Medical Oncology, Eugène Marquis Center, Rennes, France
  6. Methodology and Biostatistics Unit, Oscar Lambret Center, Lille, France
  7. Biostatistics Unit, EA2694, University Hospital and University of Lille, Lille, France
  8. Breast Unit, Department of Medical Oncology, Oscar Lambret Center, Lille, France
  9. University of Lille, Lille, France
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  
• 出版者：Springer Netherlands
• ISSN：1573-7217

文摘

Cognitive impairment, especially verbal episodic memory and executive function impairments, has been considered to be a possible adverse effect of aromatase inhibitors (AI). This phase III open-label study compared the impact of tamoxifen and AI on verbal episodic memory (Rey auditory verbal learning test—RAVLT) and other cognitive functions (visual memory, psychomotor speed, and executive functions) after 6 and 12?months of treatment in breast cancer patients undergoing adjuvant hormonotherapy. Menopausal chemo-na?ve patients with resectable breast cancer were randomly assigned (1:1) at the end of the radiotherapy to receive tamoxifen or AI. Neuropsychological assessments, self-reported quality of life, and depression assessments were performed at baseline, before any hormonal treatment, and at 6 and 12?months. Mixed design analysis models of variance was used to compare the evolution of the scores between the groups during follow-up. A total of 74 evaluable patients were enrolled (Tamoxifen arm, n?=?37; AI arm, n?=?37; letrozole n?=?18; anastrozole n?=?16; exemestane n?=?3). The median age at inclusion was 61?years (range, minimum 49–maximum 69). The patient and breast cancer characteristics were well balanced between arms. After 6?months, no significant differential effect of AI or tamoxifen was observed on the RAVLT. Moreover, considering the other cognitive measures and the quality of life questionnaires, there were also no differences between the groups during the 1-year follow-up. In this study, AI has not demonstrated worse adverse effects on cognitive functions than tamoxifen during a 1-year follow-up